Skip to main content
. 2022 Dec 9;43:187. doi: 10.11604/pamj.2022.43.187.37172

Table 3.

association between respondents’ socio-demographics and adherence to HAART

Variables Adherence
Good adherence Poor adherence χ2 P-value
Age
<43 319(61.9) 196(38.1) 1.569 0.210
≥43 281(58.1) 41(41.9)
Sex
Male 182(61.7) 113(38.3) 0.466 0.495
Female 418(59.4) 286(40.6)
Marital status
Married / cohabiting 286(61.4) 180(38.6) 1.306 0.728
Separated / divorced 39(55.7) 31(44.3)
Widowed 145(60.7) 94(39.3)
Single 130(58.0) 94(42.0)
Employment status
Employed 475(61.5) 297(38.5) 3.054 0.081
Not employed 125(55.1) 102(44.9)
Type of settlement /resident
Urban 366(61.0) 217(54.4) 4.314 0.038
Rural 234(39.0) 182(45.6)
Level of education
No formal education 45(48.4) 48(51.6) 5.825 0.016
Formal education 555(61.3) 351(38.7)
Comorbidities
No 404(59.0) 281(41.0) 1.064 0.302
Yes 196(62.4) 118(37.6)
Alcohol
No 515(63.5) 296(35.9) 21.282 <0.001
Yes 85(45.2) 103(54.8)
Disclosure
No 54(62.8) 32(37.2) 0.293 0.589
Yes 546(59.8) 367(40.2)
Family support
No 201(65.3) 107(34.7) 5.019 0.025
Yes 399(57.7) 292(42.3)
HAART combination
First line 544(64.6) 298(35.4) 46.199 <0.001
Second line 56(35.7) 101(64.3)
Number of pills per day
≤2 596(60.1) 396(39.9) FET 0.000 1.000
>2 4(57.1) 3(42.9)
HAART dosing
Once daily 269(52.2) 246(47.8) 27.148 <0.001
Twice daily 331(68.4) 153(31.6)
Food and water restriction
No 600(60.3) 395(39.7) FET 0.000 0.025
Yes 0(0.0) 4(100)
Encountered side effects
No 512(61.5) 320(38.5) 4.535 0.033
Yes 88(52.7) 79(47.3)
CD4 count
<500 332(56.1) 260(43.9) 9.591 0.002
≥500 268(65.8) 139(34.2)

HAART: highly active antiretroviral therapy; FET: Fisher’s exact test